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Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food
Allergens (NDA) was asked to deliver an opinion on lacto-N-tetraose (LNT) as a novel food (NF)
pursuant to Regulation (EU) 2015/2283. The NF is a powdered mixture mainly composed by LNT, but
also containing D-lactose and other oligosaccharides such as para-lacto-N-hexaose-2 (para-LNH-2),
lacto-N-triose II and a small fraction of other carbohydrates. It is produced by fermentation with a
genetically modified strain of Escherichia coli K-12. The information provided on the manufacturing
process, composition and specifications of the NF does not raise safety concerns. The applicant intends
to add the NF in a variety of foods, including infant and follow-on formula, foods for infants and
toddlers, foods for special medical purposes and food supplements. The target population is the general
population except for food supplements, for which the target population is individuals above 1 year of
age. The intake of LNT from the NF at the proposed use levels is unlikely to exceed the intake level of
naturally occurring LNT in breastfed infants on a body weight basis. The intake of other carbohydrate-
type compounds structurally related to LNT is considered of no safety concern. The Panel concludes that
the NF is safe under the proposed conditions of use for the proposed target populations.
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Summary
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Food Allergens (NDA) was asked to deliver a scientific opinion on lacto-N-tetraose (LNT) as a novel
food (NF) pursuant to Regulation (EU) 2015/2283. The assessment of the safety of this NF that is a
powdered mixture mainly composed of LNT, but also containing D-lactose and other oligosaccharides
such as para-lacto-N-hexaose-2 (para-LNH-2), lacto-N-triose II and a small fraction of other
carbohydrates, follows the methodology set out in the EFSA Guidance on the preparation and
presentation of an application for authorisation of a novel food Regulation (EU) 2015/2283 and in the
Commission Implementing Regulation (EU) 2017/2469 and it is based on the data supplied in the
application, information submitted by the applicant following the European Food Safety Authority
(EFSA) requests for supplementary information and additional data identified by the Panel.
The NF contains LNT as the primary ingredient (around 78% w/w dry matter) and it is considered
to be a mixture with fully characterised and related substances such as D-lactose and lacto-N-triose II.
The remaining portion of the product consists mainly of other carbohydrate-type compounds
structurally related to LNT, e.g. para-lacto-N-hexaose-2 and the ‘LNT fructose isomer’. Overall, the dry
total specified carbohydrates fraction of the LNT product adds up to 97% of the total weight. The NF
is obtained by fermentation with a genetically modified strain of Escherichia coli (K-12 DH1 MDO).
The information provided on the manufacturing process, composition and specifications of the NF
does not raise safety concerns.
The applicant intends to add the NF in a variety of foods, including infant and follow-on formula (IF
and FOF), foods for infants and young children, foods for special medical purposes and food
supplements. The target population is the general population except for food supplements, for which
the target population is individuals above 1 year of age.
Considering that LNT is a naturally occurring oligosaccharide present in human milk, the history of
human exposure to LNT concerns breastfed infants.
The Panel considers that there are no concerns regarding genotoxicity of the NF and that a no
observed adverse effect level (NOAEL) from the 90-day oral toxicity study with the NF can be
established at the highest dose of 4,000 mg/kg body weight (bw) per day.
The anticipated daily intake of LNT from the consumption of IF (only), in infants up to 16 weeks of
age, does not exceed the high intake level in breastfed infants per kg bw. The anticipated daily intake
of LNT for the proposed uses at their respective maximum use levels is unlikely to exceed the high
intake level of LNT in breastfed infants per kg bw. The maximum daily intake of the NF as food
supplements (i.e. 2 g/day) for individuals above 1 year of age also does not exceed the maximum
intake level of LNT in breastfed infants per kg bw. The intake of LNT in breastfed infants on a body
weight basis is expected to be safe also for other population groups.
The Panel notes that for other oligosaccharides present as a small fraction in the NF (i.e. lacto-N-
triose II and para-LNH-2) a comparison with exposures from human milk cannot be performed.
It is also noted that with substances of this nature the maximum feasible doses that can be used in
subchronic studies (because of viscosity and risk of nutritional imbalance) are only able to ensure a
relatively low safety margin with respect to the highest estimated daily intakes in the intended
population. However, taking into account the intrinsic nature of human milk oligosaccharides (HMOs)
with their limited absorption, the low levels in the NF, the absence of toxicologically relevant effects in
the subchronic study up to the highest dose tested and considering that infants are naturally exposed
to these substances, the Panel considers that no safety concerns arise.
Thus, the Panel concludes that the NF, mainly composed of LNT, but also containing D-lactose and
other oligosaccharides such as para-lacto-N-hexaose-2 (para-LNH-2), lacto-N-triose II and a small
fraction of other carbohydrates, is safe under the proposed conditions of use. The target population is
the general population, except for food supplements for which the target population is individuals
above 1 year of age. Food supplements are not intended to be used if other foods with added NF or
breast milk are consumed the same day.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 16 July 2018, the company Glycom A/S submitted a request to the European Commission in
accordance with Article 10 of Regulation (EU) 2015/22831 to place on the EU market lacto-N-tetraose
as a novel food.
In accordance with Article 10(3) of Regulation (EU) 2015/2283, the European Commission asks the
European Food Safety Authority to provide a scientific opinion by carrying out the assessment for
lacto-N-tetraose as a novel food ingredient.
2. Data and methodologies
2.1. Data
The safety assessment of this novel food (NF) is based on data supplied in the application and
information submitted by the applicant following EFSA requests for supplementary information.
During the assessment, the Panel identified additional data which were not included in the application
(Gorbach, 1978; Strecker et al., 1989; Rudloff et al., 1996, 2012; Gnoth et al., 2000; Chai et al., 2001;
Pfenniger et al., 2002; Asakuma et al., 2008, 2011; De Leoz et al., 2012; Rudloff and Kunz, 2012;
Goehring et al., 2014; Vazquez et al., 2017; Phipps et al., 2018).
Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in the Commission Implementing Regulation (EU) 2017/2469.2
A common and structured format on the presentation of NF applications is described in the EFSA
guidance on the preparation and presentation of a NF application (EFSA NDA Panel, 2016). As indicated
in this guidance, it is the duty of the applicant to provide all available (proprietary, confidential and
published) scientific data, including both data in favour and not in favour to supporting the safety of the
proposed NF.
This NF application includes a request for protection of proprietary data in accordance with Article
26 of Regulation (EU) 2015/2283. Data claimed to be proprietary by the applicant include:
• Detailed description of the production process – raw materials and schematic overview of the
processing (section of the dossier 2.b.1.1-4).
• Annexes to the dossier which relate to the identity, the production process, production
microorganism, composition and specifications of the NF (annex I ‘NMR analytical reports’,
annex II ‘production strain data’, annex III ‘production strain certificates’, annex IV ‘raw
materials and processing aids’, annex V ‘Certificate of Analysis and batch data’, annex VI
‘analytical methods and validation reports’, annex VII ‘Stability reports’, annex VIII ‘Laboratory
accreditation certificates’).
• ‘Intakes assessment report’ (annex X to the dossier).
• Unpublished toxicological study reports:
– Lacto-N-tetraose – Bacterial Reverse Mutation Test (Study report 2018a); In Vitro
Mammalian Cell Micronucleus Test (Study report 2018b, 2019); 14-Day Toxicity Study in
the Neonatal Rat (Study report, 2018c); 90-Day Toxicity Study in the Neonatal Rat (Study
report, 2018d);
– Lacto-N-neotetraose - In Vitro Mammalian Cell Micronucleus Test (Study report, 2016a),
90-Day Toxicity Study in the Neonatal Rat (Study report 2016b).
• Appendix B.3 to the dossier referring to the summary table of statistically significant
observations in toxicity studies with lacto-N-tetraose (LNT).
Safety of lacto-N-tetraose (LNT) as a NF
1 Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods, amending Regulation (EU) No 1169/
2011 of the European Parliament and of the Council and repealing Regulation (EC) N0 258/97 of the European Parliament and
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2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications (EFSA NDA
Panel, 2016) and the principles described in the relevant existing guidance documents from the EFSA
Scientific Committee. The legal provisions for the assessment are laid down in Article 11 of Regulation
(EU) 2015/2283 and in Article 7 of the Commission Implementing Regulation (EU) 2017/2469.
This assessment concerns only risk that might be associated with consumption of the NF under the
proposed conditions of use and is not an assessment of the efficacy of LNT with regard to any claimed
benefit.
3. Assessment
3.1. Introduction
The NF is LNT, one of the most abundant oligosaccharides within the complex fraction of human
milk oligosaccharides (HMO). The Panel notes that although LNT is the major component of the NF,
related substances (namely lacto-N-triose II and para-lacto-N-hexaose-2) are also present. The NF is
obtained by microbial fermentation using D-lactose as a substrate and D-glucose as an energy source.
LNT is chemically and structurally identical to the naturally occurring LNT in human breast milk. The
NF is intended to be used in foods for infants and young children (including infant formulas (IFs) and
follow-on formulas), foods for special medical purposes, total diet replacements for weight control,
food supplements, beverages and in a variety of other foods (e.g. dairy products, bakery wares). The
target population is the general population, except for the use as food supplement which is intended
for individuals above 1 year of age.
The applicant indicated that according to Regulation (EU) 2015/2283 this NF falls under the
following categories:
i) ‘food with a new or intentionally modified molecular structure, where that structure was not
used as, or in, a food within the Union before 15 May 1997’; and
ii) ‘food consisting of, isolated from or produced from microorganisms, fungi or algae’.
3.2. Identity of the NF
The NF is a powdered mixture mainly composed of LNT, but also containing D-lactose and
other oligosaccharides such as para-lacto-N-hexaose-2 (para-LNH-2), lacto-N-triose II and a small
fraction of other carbohydrates. It is produced by fermentation with the genetically modified strain of
Escherichia coli K12 DH1 MDO. LNT is a tetrasaccharide consisting of a terminal D-galactose linked
through a b-(1-3) bond to N-acetyl-D-glucosamine (GlcNAc), linked through a b-(1-3) bond to
D-galactose, linked through a b-(1-4) bond to the reducing end D-glucose, which is in equilibrium
between the a and b-anomeric forms. LNT is an isomer of LNnT (lacto-N-neotetraose), which contains
the same monosaccharide moieties, with the linkage between the terminal galactose and GlcNAc being
b-(1-4).
LNT is characterised by the chemical formula: C26H45O21; molecular mass: 707.63 Da; CAS No
14116-68-8; IUPAC name: Gal-(b1-3)-GlcNAc-(b1-3)-Gal-(b1-4)-Glc (Figure 1).
The structure has been confirmed by using monodimensional (1D) and two-dimensional (2D) 1H
and 13C nuclear magnetic resonance spectroscopy (NMR). The coupling constants (JH1,H2) indicate that
the pyranose ring configurations are b for all monosaccharide units, except for the reducing end
glucose, where the two anomeric forms are in equilibrium. In order to demonstrate the presence of
the b-(1-3) linkage between the terminal galactose and N-acetylglucosamine in LNT, a 2D 1H-1H
Nuclear overhauser effect spectroscopy (NOESY) report has been provided, indicating the steric
proximity of the H-1 atom of the terminal galactose unit and the H-3 atom of the N-acetyl-glucosamine
unit. In addition, the presence of the b-(1-3)-bond has been confirmed by two independent reports,
including two-dimensional 1H-1H and 1H-13C correlation experiments: zero quantum total correlation
spectroscopy (zqTOCSY), heteronuclear single quantum coherence (HSQC) and heteronuclear multiple
bond correlation (HMBC) experiments. Correlations in the HSQC spectrum were identified and assigned
based on the chemical shifts previously reported for LNT (Strecker et al., 1989). Also, the mass
fragmentation pattern in MS/MS spectrometry for LNT has been provided and is consistent with that
reported in the literature (Chai et al., 2001; Pfenneger et al., 2002; Urashima et al., 2018).
Safety of lacto-N-tetraose (LNT) as a NF
www.efsa.europa.eu/efsajournal 6 EFSA Journal 2019;17(12):5907
The LNT produced by microbial fermentation has been shown to be chemically and structurally
identical to its counterpart present in HMOs by mono- and two-dimensional NMR.
3.3. Production process
The NF is produced according to Good Manufacturing Practice (GMP) and Hazard Analysis Critical
Control Points (HACCP) principles. It is also comparable to the manufacturing processes of the already
authorised human identical milk oligosaccharides (HiMOs), such as LNnT and 2’-FL (fucosyllactose),
assessed by EFSA (2’-FL/DFL (difucosyllactose), EFSA NDA Panel, 2019).
The manufacturing process can be broadly divided into two stages. In the first stage, D-lactose and
D-glucose are converted to LNT by the adapted cellular metabolism of the production microorganism,
which uses D-glucose as an energy and carbon source, and D-lactose as a substrate for LNT
biosynthesis. The production microorganism is entirely removed from the medium by filtration at the
end of the fermentation process. The second stage of the process consists of a series of purification,
concentration and isolation steps to obtain the NF as a dried, amorphous powdered mixture.
The producing strain E. coli (K-12 DH1 MDO) used in the fermentation process for the production
of the NF, is a genetically modified derivative of the parental strain E. coli K-12 DH1
(ʎ- gyrA96 recA1 relA1 endA1 thi-1 hsdR17 supE44) that was obtained by the applicant from the
German Collection of Microorganisms and Cell cultures (DSMZ) and deposited under DSM No. 4235.
The parental strain E. coli K-12 DH1 derives from E. coli K-12 by forced random mutagenesis.
Although the species E. coli was considered not suitable for qualified presumption of safety (QPS)
status (EFSA BIOHAZ Panel, 2018), E. coli K-12 is considered as a safe and non-pathogenic or
toxigenic microorganism widely used for biotechnological applications (Gorbach, 1978; OECD, 1986;
Muhldorfer and Hacker, 1994; U.S. EPA, 1997). The whole genomes of E. coli K-12 and of other
derivative strains, including E. coli K-12 DH1, were sequenced and compared with other E. coli strains.
The results indicate that E. coli K-12 and its derivatives show genomic differences compared to
pathogenic strains (Blattner et al., 1997; Lukjancenko et al., 2010).
The genetically modified producing strain E. coli (K-12 DH1 MDO), has been deposited in the DSMZ
in Braunschweig, Germany, under DSM No. 32776. The applicant provided a detailed description of the
genetic modification process applied to the parental strain E. coli K-12 DH1 to obtain an intermediate
platform strain E. coli (K-12 DH1) MDO and the final producing microorganism E. coli (K-12 DH1 MDO).
The absence of viable cells of the producing microorganism in the NF was demonstrated by testing
five batches of the NF for bacteria from the Enterobacteriaceae family according to internationally
recognised methods (ISO 21528-1:2004, MSZ ISO 21528-2:2004). To increase the level of
reassurance, an additional and E. coli-specific method (ISO 7251:2005) has been applied for all
batches and the success criteria have been set and confirmed to be ‘absent in 10 g’ of tested product.
Furthermore, the absence of residual proteins is confirmed by an adaptation of the Bradford protein
method which has been validated to detect residual protein down to a level of 0.01%. Residual
proteins cannot be detected in the final product.
In addition, no residual DNA from the production organism was detected in five independent
batches of the NF using three quantitative polymerase chain reaction (PCR) assays (limit of
quantification (LOQ) = 0.4 pg/mg). Upon EFSA’s request, the applicant provided data to demonstrate
the validity of the method in accordance to the EFSA guidance on microorganisms used as production
organisms (EFSA FEEDAP Panel, 2018).
The Panel considers that the production process is sufficiently described and does not raise safety
concerns.
Figure 1: Structure of LNT
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3.4. Compositional data
The NF contains LNT as the primary ingredient (around 78% w/w dry matter) and is considered to
be a mixture of fully characterised and related substances such as D-lactose and lacto-N-triose II,
comprising an average of 93% of the total batch weight. The remaining portion of the product consists
mainly of other carbohydrate-type compounds structurally related to LNT, e.g. para-LNH-2 and the
‘LNT fructose isomer’. Overall, the dry total specified carbohydrates fraction of the LNT product adds
up to 97% of the total weight (mean from five batches of the NF).
Lacto-N-triose II is a metabolic intermediate of LNT (and LNnT) biosynthesis and one of the
products of LNT (or LNnT) hydrolysis (Kuhn et al., 1956), and as such occurs also naturally in breast
milk (Dabrowski et al., 1983; Hosomi and Takeya, 1988; Miwa et al., 2010). The hexasaccharide, para-
LNH-2), is an isomer/analogue of the para-LNH naturally present in human milk, firstly isolated and
described in 1977 by Yamashita et al. (1977). The ‘LNT fructose isomer’ is a product derived from LNT
by isomerisation, where the terminal glucose moiety has been isomerised to a fructose unit.
As regard to the physico-chemical properties, the LNT product can be described as white to off-
white amorphous powder or agglomerate. It is readily soluble in aqueous solutions (max. 400 mg/mL,
25°C), with poor solubility in any organic solvents.
The applicant provided batch-to-batch compositional analysis for five batches of the NF (Table 1).
LNT and the carbohydrate-type compounds have been analysed by high-performance anion exchange
chromatography coupled to pulsed amperometric detection (HPAEC-PAD) using ‘in house’ validated
methods as well as analysis by certified external international laboratories.
The microbiological purity of batches of the NF has been assessed for non-pathogenic
microorganisms (bacteria, yeasts and moulds) as general hygiene indicators as well as for selected
food-borne pathogens.
The Panel considers that the information provided on the composition of the NF is sufficient and
does not raise safety concerns.
Table 1: Batch-to-batch analysis for five batches of NF
Parameters
Batches
CPN4215
1000216 FD
CPN4215
1000316 FD
CPN4215
1000416 FD
CPN4215
1000516 FD
CPN4215
1000616 FD
Mean  SD
Physiochemical properties
Appearance Powder or agglomerates
Colour White to off white
pH (20°C, 5%
solution)
4.6 4.0 4.3 4.5 4.4 4.4  0.2
Composition
HiMS [w/w % dry
matter]
94.7 92.4 92.2 92.0 92.0 92.7  1.2
LNT [w/w % dry
matter]
80.1 80.2 77.0 76.2 78.9 78.5  1.8
D-Lactose [w/w %] 6.27 6.28 8.94 9.33 7.18 7.6  1.5
Lacto-N-triose II
[w/w %]
8.15 6.28 5.95 6.24 5.55 6.4  1.0
para-LNH-2 [w/w %] 2.38 2.85 2.48 2.93 3.21 2.8  0.3
LNT fructose isomer
[w/w %]
0.53 0.69 0.60 0.73 0.71 0.65  0.1
Sum of other
carbohydrates
[w/w %]
1.1 1.3 1.4 1.4 1.2 1.3  0.1
Total specified
carbohydrates (dry
matter) [w/w %]
98.8 97.9 96.7 97.1 97.2 97.5  0.8
Water [w/w %] 1.5 1.9 2.0 1.6 2.7 1.9  0.5
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3.4.1. Stability
Stability of NF
The bulk stability of the powdered NF produced by fermentation has been investigated in two
representative batches, in an ongoing 5-year study under real-time conditions (25°C, 60% relative
humidity (RH)) and an ongoing 2-year study under accelerated conditions (40°C, 75% RH).
Upon EFSA’s request for additional information, the applicant provided interim results of two
batches of the NF. Results on composition, sensory testing, physical and microbiological parameters
have been provided for the two batches up to 24 and 36 months for the real time stability and up to
18 and 24 months for accelerated stability studies. The results indicate that there is no appreciable
degradation of NF ingredients, no changes in impurity profile, and no alterations in the microbiological
quality of the ingredient.
Based on the data available, the Panel considers that the NF is expected to be stable for at least
24 months when stored at room temperature.
Stability of NF under the intended conditions of use
The stability of the LNT ingredients in powdered IF has also been investigated. Long-term storage
(up to 12 months) at various temperatures (4, 20, 30 and 37°C) showed that LNT in the IF (containing
other HiMOs, long-chain polyunsaturated fatty acids (LC-PUFA), vitamins and minerals to mimic the
intended conditions of use) is stable under the tested conditions since no appreciable variations of the
HiMO levels over time were observed.
No stability data for LNT in other food matrices have been provided. LNnT, the constitutional isomer
of LNT has been demonstrated to be stable in various food matrices, including yoghurts, ready-to-
drink flavoured milk and citrus fruit beverages. All stability studies on LNnT were conducted using
formulations representative of commercial food products on the market and under typical processing
(i.e., pasteurisation and/or UHT heating) and typical storage conditions (e.g. temperature and shelf-
life) for such products.
Based on the highly similar structure, the applicant assumes that the stability properties of LNnT
and LNT are comparable.
The Panel considers that the available data provide sufficient information with respect to the
stability of the NF in the food matrices.
Parameters
Batches
CPN4215
1000216 FD
CPN4215
1000316 FD
CPN4215
1000416 FD
CPN4215
1000516 FD
CPN4215
1000616 FD
Mean  SD
Ash, sulfated
[w/w %]
0.15 0.11 0.08 0.07 0.09 0.1  0.03
Microbiological parameters
Aerobic mesophilic
total plate count
[CFU/g]
< 10 < 10 < 10 < 10 < 10 < 10
Enterobacteriaceae
[in 10 g]
Absent Absent Absent Absent Absent Absent
Salmonella spp.[in
25 g]
Absent Absent Absent Absent Absent Absent
Cronobacter
(Enterobacter)
sakazakii [in 10 g]
Absent Absent Absent Absent Absent Absent
Listeria
monocytogenes[in
25 g]
Absent Absent Absent Absent Absent Absent
Bacillus cereus
[CFU/g]
< 10 < 10 < 10 < 10 < 10 < 10
Yeasts [CFU/g] < 10 < 10 < 10 < 10 < 10 < 10
Moulds [CFU/g] < 10 < 10 < 10 < 10 < 10 < 10
HiMS: human identical milk saccharides; CFU: colony forming units; LNT: lacto-N-tetraose; SD: standard deviation.
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3.5. Specifications
The specifications of the NF as proposed by the applicant are presented in Table 2. The parameters
include the main components of the mixture of HiMS (predominantly LNT), the principal raw material
D-lactose and lacto-N-triose II and also two other oligosaccharides, para-lacto-N-hexaose-2 and ‘LNT
fructose isomer’.
The sum of relevant HiMS (LNT, lactose and lacto-N-triose II) has been introduced by the applicant
as a parameter with a minimum level set at 90% to ensure a highly consistent product quality. The
LNT content is specifically set with a minimum of 70% (dry matter).
The Panel noted that the efficiency of the production process when compared to the one of its
constitutional isomer LNnT produced by fermentation, is relatively low (lacto-N-triose II and D-lactose
levels up to 10 and 12%, respectively). This fact has been explained by the applicant as a change in
the production process to reduce the use of solvents, while maintaining a high (≥90% w/w dry matter)
sum of HiMS.
Another parameter called ‘sum of other carbohydrates’ has been introduced, to include other
carbohydrates individually present in low concentration, up to a total amount of 5%.
Microbiological parameters for Listeria monocytogenes, Cronobacter (Enterobacter) sakazakii and
Bacillus cereus are monitored through internal specifications.
Analyses were performed using internationally recognised methods or newly developed and
validated analytical protocols at Glycom’s Research & Development Department and confirmed by
accredited laboratories.
The Panel considers that the information provided on the specification of the NF is sufficient and
does not raise safety concerns.
Table 2: Specifications of the NF
Description: the NF is a purified, white to off-white powder that is produced by a microbial process and
contains lacto-N-tetraose (LNT) and limited levels of lactose, lacto-N-triose II and lacto-N-hexaose-2.
Source: A genetically modified strain of Escherichia coli K-12 DH1 MDO
Parameter Specification Method
Identification (LNT) RT of standard  3% HPLC/UV
Sum of HiMS(1) (dry matter) ≥ 90.0 w/w % HPLC/UV and HPLC/PAD
LNT (dry matter) ≥ 70.0 w/w % HPLC/UV and HPLC/PAD
D-Lactose ≤ 12.0 w/w % HPAEC/PAD
Lacto-N-triose II ≤ 10.0 w/w % HPAEC/PAD
para-LNH-2 ≤ 3.5 w/w % HPAEC/PAD
LNT fructose isomer ≤ 1.0 w/w % HPLC/CAD
Sum of other carbohydrates ≤ 5.0 w/w % HPLC/CAD and HPAEC/PAD
pH (20°C, 5% solution) 4.0–6.0 Eur. Ph. 9.2 2.2.3 (07/2016:20203)
Water ≤ 6.0 w/w % Karl-Fisher
Ash, sulfated ≤ 0.5 w/w % Eur. Ph. 9.2 2.4.14 (04/2010:20414)
Residual protein ≤ 0.01 w/w % Bradford assay (UV spectroscopy) (2)
Microbiological Parameters
Aerobic mesophilic total plate count ≤ 1,000 CFU/g ISO 4833-1:2014
Enterobacteriaceae ≤ 10 CFU/g ISO 21528-1:2004, MSZ ISO 21528-2:2004
Salmonella spp. Absent in 25 g ISO 6579:2006
Yeasts ≤ 100 CFU/g ISO 7954:1999
Moulds ≤ 100 CFU/g ISO 7954:1999
Residual endotoxins ≤ 10 EU/mg Eur. Ph. 2.6.14
LNT: lacto-N-tetraose; CFU: colony forming units; EU: endotoxin units; Eur. Ph.: European Pharmacopoeia; HiMS: Human
identical Milk Saccharides; HPLC: high-performance liquid chromatography; CAD: charged aerosol detection; PAD: pulsed
amperometric detection KF: Karl–Fischer; RT: retention time; ISO: International Organization for Standardization; UV: ultraviolet.
(1): Sum of carbohydrates LNT, lactose and Lacto-N-triose II; (2) LOR (reporting limit) = 17 mg/kg.
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3.6. History of use of the NF and/or of its source
3.6.1. History of use of the NF
The applicant states that the NF does not have a history of use.
Two other HiMOs (i.e. the constitutional isomer LNnT and 2’-FL) produced by the same applicant by
chemical synthesis and by fermentation with E. coli K-12 have been included in the European novel
food list ((EU) 2018/1023) as well as granted GRAS status in the US (FDA, 2016) and considered novel
food ingredients in Israel and Singapore. The HiMO produced by fermentation was considered
substantially identical to the one obtained by chemical synthesis. LNnT can be added in several food
categories alone or in combination with 2’-FL at a dose up to 0.6 g L or kg ((EU) 2017/2470).3
3.6.2. Consumption of oligosaccharides constituent of the NF in breast milk
Human breast milk contains a family of structurally related oligosaccharides, known as HMOs, as
the third largest solid components. The highest concentrations of HMOs occur in human colostrum (20
to 25 g/L), and concentrations between 5 to 20 g/L occur in mature human milk (Thurl et al., 2010;
Bode, 2012; Urashima et al., 2018). HMOs amount and composition vary among mothers and over the
course of lactation. LNT belongs to the subfraction of ‘neutral core’ HMOs, characterised by the
presence of N-acetyl-D-glucosamine (GlcNAc) and that accounts for 10–20% of the total HMO (Thurl
et al., 2010; Rijnierse et al., 2011; Bode, 2012). In addition, LNT is one of the most abundant HMOs
along with 2’-FL, 6’-sialyllactose, lacto-N-fucopentaose I and LNnT.
Although the HMO pattern depends on the genetic background of the mother, core HMOs such as
LNT and LNnT, are present in all types of milks from all mothers’ phenotypes (Erney et al., 2000; Kunz
et al., 2016). The biological relevance of the structural difference between LNT and LNnT, i.e. type 1 vs
type 2 linkage between the terminal Gal and next to GlcNAc (and the respective ratio between the 2
forms) is not clear.
Several publications on HMO and LNT in human milk have been provided by the applicant. The
amount of LNT in human milk, as for other HMOs, is genetically determined and also depending on the
lactation period, with higher levels reported in colostrum (Coppa et al., 1999, 2001; Erney et al., 2000;
Asakuma et al., 2008, 2011; Thurl et al., 2010, 2017; De Leoz et al., 2012; Galeotti et al., 2012, 2014;
Spevacek et al., 2015; Austin et al., 2016; McGuire et al., 2017). Thurl et al. (2017) summarised the
findings from 21 studies and reported that the content of LNT in milk from mothers who delivered at
the end of gestation period ranged from 0.59 to 0.98 g/L (average 0.79 g/L). It was noted that the
amount of LNT was slightly more abundant (ranging from 0.39 to 1.68 g/L, average 1.04 g/L) in
mothers who delivered pre-terms. Erney et al. (2001) reported an average concentration of 0.76 g/L
(with a maximum of 2.74 g/L) in pooled milk samples from different lactating phases. LNT was found
in all samples collected from 264 mothers.
Based on the mean and the highest reported occurrence levels of LNT in human milk as reported
by Erney et al. (2001) and considering the average and high daily intake of breast milk (800 mL and
1200 mL, respectively) for infants from 0 to 6 months (EFSA NDA Panel, 2013), the daily intake levels
of LNT from human milk for a 6.7 kg body weight (bw) infant (EFSA Scientific Committee, 2012) have
been calculated (Table 3). This default bw used by the NDA Panel is for an infant of 3–6 months of
age, who is more likely to consume such amount of human milk.
Oligosaccharides have also been detected in domestic farm animal milk, however at lower
concentrations as compared to human milk (Urashima et al., 2012, 2013; Aldredge et al., 2013;
Albrecht et al., 2014).
Safety of lacto-N-tetraose (LNT) as a NF
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The Panel noted that although the main component of the NF is LNT, other fractions such as
lactose, lacto-N-triose II and para-LNH-2 are present in different amounts. While lactose is the most
represented molecule in human breast milk, less is known for the other two fractions.
Lacto-N-triose II is a metabolic intermediate of LNT and also produced from the catabolism of LNT
and LNnT (Miwa et al., 2010; Honda et al., 2013; Bidart et al., 2016; Thongaram et al., 2017) by gut
microbiota fermentation. para-LNH-2 is an isomer of LNH, present in human milk mainly as mono- and
difucosyl- derivatives (Yamashita et al., 1977; Albrecht et al., 2011; Thurl et al., 2017).
The presence of these oligosaccharides in human milk has not been quantified.
3.7. Proposed uses and use levels and anticipated intake
3.7.1. Target population
The target population proposed by the applicant is the general population, except for food
supplements for which the target population is individuals above 1 year of age.
3.7.2. Proposed uses and use levels
The NF is intended to be added to a variety of foods, at the maximum use levels as indicated in
Table 4. The Panel notes that for ‘Food for special medical purposes’ the applicant did not propose
either maximum use levels or maximum intake levels.
The applicant also intends to market the NF as food supplement, at the maximum daily intake of
2 g, for individuals above 1 year of age. Food supplements are not intended to be used if other foods
with added LNT are consumed the same day.
Table 3: Estimated daily intake levels of LNT from human milk (800 mL and 1,200 mL) for infants
of 6.7 kg bw, based on mean and high concentration of 0.76 g/L and 2.74 g/L,
respectively, of LNT measured in human milk
Daily intake levels (mg/kg bw)
from 800 mL of human milk
Daily intake levels (mg/kg bw)
from 1200 mL of human milk
Mean concentration High concentration Mean concentration High concentration
LNT 91 327 136 491
bw: body weight.
Table 4: Proposed Food Uses and maximum use Levels for LNT
EU food
category
number
Food category name Proposed Maximum use level
1 Dairy products and analogues
1.1 Unflavoured pasteurised and unflavoured
sterilised (including UHT) milk
1.0 g/L
1.2/1.3 Unflavoured fermented milk-based products 1.0 g/L beverages
10 g/kg products other than beverages
1.4 Flavoured fermented milk-based products
including heat-treated products
1.0 g/L beverages
10 g/kg products other than beverages
7 Bakery wares
7.2 Fine bakery wares. Cereal bars only 10 g/kg
13 Foods for special groups (FSG)
13.1 Foods for infants and young children
13.1.1 Infant formula as defined in Regulation (EU)
No 609/2013
0.8 g/L in the final product ready for use, marketed as
such or reconstituted as instructed by the
manufacturer
13.1.2 Follow-on formula as defined in Regulation
(EU) No 609/2013
0.6 g/L in the final product ready for use, marketed as
such or reconstituted as instructed by the
manufacturer
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3.7.3. Anticipated intake of the NF
Anticipated intake of the NF from the consumption of infant formula in infants up to
16 weeks of age
IF is expected to be the only food consumed by infants aged 0–16 weeks who are not breastfed.
The high consumption of IF has been estimated to be 260 mL/kg bw per day for infants aged
0–16 weeks (EFSA Scientific Committee, 2017). Based on the maximum proposed use level of the NF
(0.8 g/L in IF), the high intake of the NF from IF alone is estimated to be 208 mg/kg bw per day.
Considering the mean content of 78% for LNT in the NF (as indicated in Table 1), the daily intake
of LNT from the consumption of IF added with the NF corresponds to approximately 162 mg/kg bw for
LNT. The Panel notes that the anticipated daily intake of the NF from the consumption of IF (only)
does not exceed the estimated high daily intake of LNT in breastfed infants per kg/bw (Table 3).
Anticipated intake of LNT from the proposed uses and use levels of the NF
The applicant estimated the daily intake of the NF by using the EFSA Food Additive Intake model
(FAIM) tool (FAIM 2.0, 2017) and compared the intake to surveys conducted in UK (NDNS and its
complement DNSIYC (Diet and Nutrition Survey of Infants and Young Children)). However, considering
that the food categories in the FAIM tool, which are based on Regulation (EC) 1333/2008, do not allow
a precise matching with the food categories proposed for the NF, the intake estimations performed by
the applicant resulted in high and uncertain estimated intakes. Thus, EFSA performed a refined
estimate of the anticipated daily intake of the NF, at the maximum proposed use levels of the NF, using
individual data from EU dietary surveys (EFSA, 2011) and by applying the FoodEx2 classification
(Table 5). The lowest and highest mean and 95th percentile anticipated daily intake of the NF for all
subjects, among the EU dietary surveys, are presented in Table 6.
The refined anticipated daily intake of the NF for each population group from each EU dietary
survey is available in the excel file annexed to this scientific opinion (under ‘Supporting information’).
EU food
category
number
Food category name Proposed Maximum use level
13.1.3 Processed cereal-based food and baby food
for infants and young children as defined in
Regulation (EU) No 609/2013
0.6 g/L in the final product ready for use, marketed as
such or reconstituted as instructed by the
manufacturer
5 g/kg for products other than beverages
13.1.4 Milk-based drinks and similar products
intended for young children
0.6 g/L in the final product ready for use, marketed as
such or reconstituted as instructed by the
manufacturer
5 g/kg for products other than beverages
13.2 Foods for special medical purposes as defined in Regulation (EU) No 609/2013
13.2 Foods for special medical purposes as
defined in Regulation (EU) No 609/2013
On case-by-case basis
13.3 Total diet replacement for weight control as defined in Regulation (EU) No 609/2013
13.3 Total diet replacement for weight control as
defined in Regulation (EU) No 609/2013
2.0 g/L beverages
20 g/kg products other than beverages
14 Beverages
14.1.4 Flavoured drinks 1.0 g/L
UHT: ultra-high temperature.
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Table 5: FoodEx2 categories and maximum use levels of the NF used in the refined estimate of the
anticipated daily intake of the NF using individual data from EU dietary surveys
CODE
FoodEx2
Level
Food
category
Maximum use level of
the NF mg/100 g
A02LV 5 Cow milk 100
A0CXA 5 European buffalo milk 100
A02MC 5 Sheep milk 100
A02 MB 4 Goat milk 100
A02MV 3 Butter milk 100
A02NQ 4 Yoghurt drinks 100
A02NR 4 Probiotic milk-like drinks 100
A02NV 5 Kefir 100
A02NE 4 Yoghurt 1,000
A00EY 4 Cereal bars 1,000
A00EZ 4 Cereal bars plain 1,000
A00FA 4 Cereal bars mixed 1,000
A03PZ 4 Infant formulae, powder 650
A03QE 4 Infant formulae, liquid 80
A03QK 4 Follow-on formulae, powder 485
A03QQ 4 Follow-on formulae, liquid 60
A03QZ 3 Cereals with an added high protein food which have to be
reconstituted
300
A03QY 3 Simple cereals which have to be reconstituted 300
A0BZF 3 Cereals with added high protein food reconstituted 60
A0BZE 3 Simple cereals for infants and children reconstituted 60
A03RA 3 Biscuits, rusks and cookies for children 500
A03RC 2 Ready-to-eat meal for infants and young children 500
A03RB 3 Pasta for children 500
A03RN 3 Fruit and vegetable juices and nectars specific for infants
and young children
60
A03RP 3 Special food for children’s growth 60
A03RT 4 Total daily diet replacement for weight reduction 2,000
A0EQN 5 Soft drinks with minor amounts of fruits or flavours 100
A03EA 5 Soft drink with fruit juice (fruit content below the minimum
for nectars)
100
A03EX 5 Soft-drink, flavoured, no fruit 100
A03FQ 4 Cola Type drinks 100
Table 6: Ranges among EU surveys of the estimated daily intake of the NF (mg/kg bw), based on
the individual data from the EFSA Comprehensive Food Consumption Database
Age groups
Number of EU
dietary
surveys
Estimated daily intake of the NF – all subjects
(mg/kg bw)
Range of means (lowest and
highest)
among EU dietary surveys
Range of 95th percentile (lowest
and highest)
among EU dietary surveys
Infants
(up to 11 months)
11 33–209 82–685
Young children or
toddlers
(12–35 months)
14 38–154 119–430
Other children
(3–9 years)
19 18–93 47–234
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Based on 78% mean LNT content in the NF (Table 1), the refined anticipated daily intake of LNT is
calculated from the highest 95th percentile anticipated daily intake of the NF (Table 7).
The Panel notes that the highest estimated 95th percentile intake considering 78% LNT content
(i.e. 534 mg/kg bw corresponding to 78% of 685 mg/kg bw) on the basis of 11 dietary surveys
covered by the EFSA Food Consumption Database, is approximately 10% above the high estimate for
LNT from human milk (i.e. 491 mg/kg bw) in infants (up to 11 months).
Considering that the exposure of LNT from human milk is only exceeded in one out of 11 dietary
surveys included in the EFSA Food Consumption Database (Table 6 and excel file annexed under
‘Supporting information’) and the conservative assumption underlying this type of intake assessment,
in particular, assuming that all foods of the proposed food categories consumed by infants are added
with the NF at the maximum proposed use levels, the Panel considers it unlikely that infants (up to
11 months) would exceed high intake levels estimated for LNT intake from human milk.
Age groups
Number of EU
dietary
surveys
Estimated daily intake of the NF – all subjects
(mg/kg bw)
Range of means (lowest and
highest)
among EU dietary surveys
Range of 95th percentile (lowest
and highest)
among EU dietary surveys
Adolescents
(10–17 years)
18 7–24 19–61
Adults
(18–64 years)
19 4–15 17–45
Elderly
(≥ 65 years)
18 4–13 16–38
Pregnant women 2 3–13 8–39
Lactating women 2 10–14 37–38
NF: novel food; bw: body weight.
Table 7: Estimated daily intake of LNT (mg/kg bw) from the highest 95th percentile of intake of the
NF, based on 78% purity (mean content as per compositional data)
Estimated daily intake
(mg/kg bw)
Age groups
For the NF
Highest 95th percentile among EU
dietary surveys (as reported in table 6)
For LNT
Highest 95th percentile among EU
dietary surveys
Infants
(up to 11 months)
685 534
Young children or
toddlers
(12–35 months)
430 335
Other children
(3–9 years)
234 182
Adolescents
(10–17 years)
61 48
Adults
(18–64 years)
45 35
Elderly
(≥ 65 years)
38 29
Pregnant women 39 30
Lactating women 38 30
bw: body weight.
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Anticipated intake of LNT from food supplements
The applicant has proposed a maximum daily intake of 2 g of the NF as food supplements for
individuals above 1 year of age. Food supplements are not intended to be used if other foods with
added LNT are consumed the same day. For toddlers (aged 12–35 months), food supplements are not
intended to be used if breast milk or other foods with added NF or LNT are consumed the same day.
Considering the mean content of 78% for LNT in the NF the maximum daily intake from food
supplements of the NF (i.e. 2 g/day) results in a maximum daily intake of 131 mg/kg bw, for toddlers
with bw of 11.9 kg (default bw value for toddlers (EFSA Scientific Committee, 2012)). For individuals
above 3 years of age, the maximum daily intake of the NF from food supplements on a bw basis
would be lower than that for toddlers.
The Panel notes that the maximum daily intake of LNT from the use of NF as food supplements
(i.e. 2 g/day) for individuals above 1 year of age does not exceed the estimated high daily intake of
LNT from human milk calculated for infants on a bw basis (Table 3).
3.7.4. Combined intake from the NF and other sources
The Panel noted that the NF, LNT and related minor fractions (mainly lacto-N-triose II and para-
LNH-2), is not authorised for use in food categories other than those proposed for the NF under
assessment. Therefore, the only additional source for these oligosaccharides is human milk.
Food supplements are not intended to be used if other foods with added LNT or breast milk are
consumed the same day.
3.8. Absorption, distribution, metabolism and excretion (ADME)
There are no data submitted for the NF or LNT.
HMOs, including LNT, are considered ‘non-digestible oligosaccharides’ (EFSA NDA Panel, 2014) since
they do not undergo any significant digestion in the upper gastrointestinal tract (Brand-Miller et al.,
1995, 1998; Engfer et al., 2000; Chaturvedi et al., 2001; Gnoth et al., 2001; Rudloff and Kunz, 2012).
Brand-Miller et al. (1995, 1998) reported that HMOs, consumed as a load (a purified
oligosaccharide fraction from human milk), are fermented in the colon by intestinal microbiota.
Chaturvedi et al. (2001) and Coppa et al. (2001) reported that 97% and 40-50%, respectively, of the
ingested HMOs are excreted unchanged in faeces of breastfed infants. Furthermore, approximately
1–2% of the ingested amounts of HMOs is excreted unchanged in the infants’ urine (Rudloff et al.,
1996; Gnoth et al., 2000; Goehring et al., 2014; Vazquez et al., 2017; EFSA, NDA Panel 2019).
Specifically, for LNT, it has been observed that an infant breastfed may receive approximately
50-100 mg for each suckling and that an amount up to 3 mg in a day is found in the urine (Rudloff
and Kunz, 2012; Rudloff et al., 2012), therefore confirming the trend of HMOs family.
Based on information available on HMOs the Panel considers that limited digestion of the NF occurs
in the upper gastrointestinal tract and that only small amounts are expected to be absorbed. Moreover,
there are no indications that the absorption of LNT, which is the main constituent of the NF, or other
components may differ from that of equivalent components in the human milk.
3.9. Nutritional information
The NF is mainly composed by the non-digestible oligosaccharide LNT. The Panel considers that
consumption of the NF at the proposed use levels is not nutritionally disadvantageous.
3.10. Toxicological information
The list of toxicological studies, which were provided and claimed proprietary by the applicant, is
reported in Table 8. These studies were conducted with the NF (batch CPN4215 1000416FD), which
was constituted by 77% w/w dry matter of LNT (6% of lacto-N-triose II and 2.5% para-LNH-2; total
of 96.7% specified carbohydrates, 9% lactose included).
The applicant also provided toxicological studies on LNnT, the isomer of LNT, which was obtained
by chemical synthesis and microbial fermentation using genetically modified strains of E. coli K-12. The
Panel considers that these toxicological studies on LNnT can provide supporting evidence for the safety
assessment of the NF.
Safety of lacto-N-tetraose (LNT) as a NF
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3.10.1. Genotoxicity
The potential genotoxicity of the NF was investigated in a bacterial reverse mutation test and an
in vitro mammalian cell micronucleus test (Phipps et al., 2018, unpublished study reports, 2018a,b,
2019). These studies were conducted in compliance with Organisation for Economic Co-operation and
Development (OECD) principles of Good Laboratory Practice (GLP) (OECD, 1998a) and in accordance
with the OECD test guidelines No 471 (OECD, 1997) and 487 (OECD, 2016).
The in vitro assessment of the mutagenic potential of the NF was performed with histidine-
dependent auxotrophic mutants of Salmonella Typhimurium, strains TA1535, TA1537, TA98 and TA100,
and a tryptophan-dependent mutant of E. coli, strain WP2 uvrA (pKM101), that were exposed to the
NF diluted in water at concentrations up to 5,106.1 lg/plate either in the presence or absence of liver
microsomal fractions (S9). No substantial, reproducible or dose-related increases in revertant colony
numbers over control counts were observed with any of the strains following exposure to LNT at any
concentration (irrespective of the presence or absence of S9). No evidence of toxicity was obtained
following exposure to the NF. Therefore, the NF showed to be non-mutagenic at concentrations up to
5106.1 lg/plate, in the absence or presence of metabolic activation.
In the in vitro mammalian cell micronucleus test, concentrations of LNT up to 2,042.44 lg/mL were
tested to assess the potential of LNT to cause an increase in the induction of micronuclei in in vitro
cultured human peripheral blood lymphocytes in the presence or absence of metabolic activation (S9
fraction). No statistically significant increases in the number of binucleate cells containing micronuclei
both after 3-hour treatment in the presence of S9 mix or following 20-hour treatment in the absence
of S9 were recorded. However, as also reported by Phipps et al. (2018) ‘following short-term exposure
in the absence of S9, a statistically significant increase (p < 0.05) in the percentage of micronucleated
cells was observed at the highest LNT concentration (2,042.44 lg/mL) compared with vehicle controls,
which was also associated with a statistically significant linear trend (p < 0.05). However, as the mean
value (10.5) was below the laboratory historical vehicle control upper limit (11.1), the increase at this
concentration was considered biologically irrelevant and the results were considered negative overall’.
Since according to OECD TG487, these data should be considered ‘neither clearly negative nor clearly
positive’ the NDA Panel decided to request further tests. At the repetition of the in vitro test applying
the same experimental conditions clear negative results were obtained (unpublished study report,
2019). The NF did not show any evidence of clastogenicity or aneugenicity in the absence and
presence of metabolic activation.
Based on the results of these studies, the Panel considers that there are no concerns regarding
genotoxicity of the NF.
3.10.2. Repeated dose toxicity studies
The applicant provided a 14-day DRF (dose range finding) repeated dose oral toxicity study where
groups of eight Crl:CD(SD) neonatal rats/sex were given water (control), 3,250 and 4,000 mg/kg bw
per day of LNT by oral gavage starting from day 7 of age (unpublished study report, 2018c). The
highest dose is considered by the author to be close to the maximum feasible dose due to limited
solubility in water and high viscosity of the prepared formulation and aligned with the doses selected
for the assessment of its isomer LNnT (up to 5,000 mg/kg bw per day, Coulet et al., 2013, EFSA NDA
Panel, 2015). There were no deaths or any variations in clinical signs, body weight or macroscopic
pathology attributable to LNT. Clinical pathology parameters were not assessed. Since the NF up to the
Table 8: List of toxicological studies with the NF provided by the applicant
Test material Reference Type of study
NF
(77% LNT)
Unpublished study report, 2018a
Phipps et al., 2018;
Bacterial reverse mutation test (Ames test)
Unpublished study report, 2018b, 2019
Phipps et al., 2018;
In vitro mammalian Cell Micronucleus Test
Unpublished study report, 2018c
Phipps et al., 2018;
14-day DRF repeated dose oral toxicity study in
neonatal rats
Unpublished study report, 2018d
Phipps et al., 2018
90-day GLP repeated dose oral toxicity study in
neonatal rats
LNT: lacto-N-tetraose; DRF: dose range finding; GLP: Good Laboratory Practice.
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highest tested dose of 4,000 mg/kg day did not cause any adverse effect, the highest dose was
considered a suitable high dose for the subsequent 90-day study in neonatal rats.
In the 90-day study groups of 10 Crl:CD(SD) neonatal rats/sex group were given water (control),
1,000, 2,500 or 4,000 mg/kg bw per day of LNT by oral gavage starting from day 7 of age once daily
for at least 90 days, until the day before necropsy (Phipps et al., 2018; unpublished study reports,
2018d). An additional control group was treated with oligofructose powder (a non-digestible
oligosaccharide permitted in infant nutrition) at 4,000 mg/kg bw per day, to compare any effects
related to the general fibre-like characteristics at the same high dose.
This study has been designed based upon the OECD TG408 (OECD, 1998b), but has been adapted
(i.e. use of juvenile animals) to consider the requirements for toxicity testing of new chemical entities
for use in the paediatric population (as was suggested by US FDA, 2006 and EMEA, 2008). There were
no deaths or any variations in clinical signs, functional observation battery tests, macroscopic and
microscopic examinations attributable to LNT. Variations in food consumption (decreased in males at
top dose in the last month of treatment) and in body weight (transient increase in the first two weeks
of treatment at intermediate and high dose, mainly in females and similar to the reference control)
were recorded. In addition variations in some haematological (i.e. levels of some red blood cells (RBC)-,
white blood cells (WBC)-related parameters and platelets at top dose in males or females) and blood
chemistry parameters (fluctuations in transaminases, urea, creatinine, cholesterol and electrolytes levels),
increase in body weight of females at the time of vaginal opening and increase in absolute organ
weights in females (i.e. kidneys, liver, ovary and spleen) and males (i.e. pituitary and testes) were also
recorded (Appendix A). The findings observed were of low magnitude, without dose correlation,
sometimes occurring only in one gender or at the end of recovery period and are considered by the
Panel as unlikely to be treatment-related.
Statistically significant differences that have been observed in groups treated with the NF are
reported in Appendix A.
The author of the study concluded that under the experimental condition applied, the dose of
4,000 mg/kg bw per day of LNT is considered as the no-observed-adverse-effect-level (NOAEL). The
Panel notes that this specific experimental design, with treatment of animals by gavage prior to
weaning, may result in high variability in several parameters. However, considering the absence of
variations of toxicological relevance, the Panel agrees with the conclusion.
3.10.3. Toxicological studies conducted with lacto-N-neotetraose
In addition to the technical reports of the toxicological studies conducted with LNT, the applicant
also provided information about studies conducted with the constitutional isomer LNnT when produced
by fermentation using the same E. coli K-12 DH1. The Panel assessed this NF obtained by chemical
synthesis (EFSA, NDA Panel, 2015) and these two new studies from 2016 were not assessed.
Considering the very high similarity between the two constitutional isomers the Panel is of the view
that such studies can be considered as supportive evidence for the assessment of LNT.
The applicant reported that in studies conducted following OECD guidelines and in accordance with
GLP principles, LNnT (purity 94.4%) did not elicit adverse effects in any of the tested doses or
concentrations. No signs of mutagenicity, clastogenicity or aneugenicity in genotoxicity studies were
noted. In the 90-day oral study in the rat the highest dose of 5,000 mg/kg bw per day was identified
as NOAEL.
3.10.4. Human data
No human intervention studies with LNT have been provided by the applicant and no reference to
human data was made. The Panel noted that studies with the constitutional isomer LNnT obtained by
Table 9: List of toxicological studies conducted with LNnT produced by fermentation
Test
material
Reference Type of study Experimental details
LNnT Unpublished study report,
2016a
In vitro mammalian Cell
Micronucleus Test
512, 1,600, 2,000 lg LNnT/mL;  S9
Unpublished study report,
2016b
90-day GLP repeated dose oral
toxicity study (neonatal rat)
10 Wistar rats sex/group; 1,000,
2,500, 5,000 mg/kg bw per day
LNnT: lacto-N-neotetraose; GLP: Good Laboratory Practice; bw: body weight.
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chemical synthesis have been conducted in adults and infants, and that data were overall sufficient to
conclude about the safety of its use under the proposed conditions (EFSA NDA Panel, 2015).
The Panel considers the information as supportive for the assessment of LNT.
3.11. Allergenicity
The protein content in the NF is very low with a level that is below 0.01% (w/w) (limit of reporting
17 mg/kg) as indicated in the specifications (Table 2). The applicant provided evidence for the absence
of microorganisms in the NF.
In addition, the applicant has assessed the allergenic potential of introduced proteins as a result of
the genetic modification of the E. coli K-12 host (which itself is recognised as non-allergenic) using the
search algorithms provided by the Allergen Online tool (version 17) of the University of Nebraska
(FARRP, 2017). No sequence alerts for potential allergenicity were identified.
The Panel considers that the likelihood of allergenic reactions to the NF is very low.
4. Discussion
The NF is a powdered mixture mainly composed by LNT, but also containing D-lactose and other
oligosaccharides such as para-lacto-N-hexaose-2 (para-LNH-2), lacto-N-triose II and a small fraction of
other carbohydrates. The NF is obtained by microbial fermentation with a genetically modified strain of
E. coli K-12. The information provided on the manufacturing process, composition and specifications of
the NF, including absence of DNA from the producing microorganisms, does not raise safety concerns.
The applicant intends to add the NF to a variety of foods, including IF and follow-on formula, foods
for infants and young children, foods for special medical purposes and food supplements. The target
population is the general population except for food supplements, for which the target population is
individuals above 1 year of age.
Considering that LNT is a naturally occurring oligosaccharide present in human milk, the history of
human exposure to LNT concerns breastfed infants. LNT is one of the most abundant HMO along with
2’-FL, 6’-SL, lacto-N-fucopentaose I and LNnT. The Panel notes that a safety assessment of its
constitutional isomer (LNnT) when chemically synthesised has been carried out by EFSA (EFSA NDA Panel,
2015). The Panel also noted that LNnTwhen obtained by fermentation (E. coli K-12 DH1) has been included
in the European novel food list. A mixture of other HiMOs (2’-FL and DFL) produced by fermentation using
the same E. coli strain and genotype has been recently assessed (EFSA NDA Panel, 2019).
The Panel considers that there are no concerns regarding genotoxicity of the NF. The highest dose
of 4,000 mg/kg bw per day used in the 90-day oral toxicity study conducted in neonatal rats was
considered as the NOAEL.
The Panel notes that the anticipated daily intake of LNT in the NF from the consumption of IF
(only), in infants up to 16 weeks of age, does not exceed the highest intake level of LNT in breastfed
infants on a bw basis. The anticipated daily intake of the NF for the proposed uses at their respective
maximum use levels in the other population categories is unlikely to exceed the highest intake level of
LNT in breastfed infants on a bw basis. Thus, since the intake in breastfed infants on a bw basis is
expected to be safe also for other population groups, and taking into account supportive evidence
provided by human intervention studies that involved the isomer LNnT and were conducted with adults
and infants, the Panel considers that the intake of the NF for the proposed uses at their respective
maximum use levels can be considered safe.
The maximum daily intake of the NF as food supplement (i.e. 2 g/day) for individuals above one
year of age does not exceed the highest intake level of LNT in breastfed infants per kg bw. Food
supplements are not intended to be used if other foods with added LNT (as well as breast milk for
young children) are consumed on the same day.
The Panel notes that for other oligosaccharides present as a small fraction in the NF (i.e. lacto-N-
triose II and para-LNH-2) a comparison with exposures from human milk cannot be performed.
When comparing the NOAEL from the 90-day toxicity study with the estimated exposure per
population category (at 95th percentile; Table 7) the margins of exposure are ranging from 7 to 138. It is
also noted that with substances of this nature the maximum feasible doses that can be used in subchronic
studies (because of viscosity and risk of nutritional imbalance) are only able to ensure a relatively low
safety margin with respect to the highest estimated daily intakes in the intended population.
However, taking into account the intrinsic nature of HMOs with their limited absorption, the low
levels in the NF, the absence of toxicologically relevant effects in the subchronic study up to the
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highest dose tested and considering that infants are naturally exposed to these substances, the
Panel considers that no safety concerns arise.
For foods for special medical purposes, the applicant did not propose maximum use levels and the
Panel considers that the maximum use levels of the NF should not be higher than the maximum levels
specified for the proposed food uses or the maximum daily intake proposed for food supplements.
5. Conclusions
The Panel concludes that the NF, composed of LNT and other structurally related oligosaccharides,
is safe under the proposed conditions of use. The target population is the general population, except
for food supplement for which the target population is limited to individuals above 1 year of age.
Food supplements are not intended to be used if other foods with added LNT or breast milk are
consumed the same day.
The Panel could not have reached the conclusions on the safety of the NF under the proposed
conditions of use without the following data claimed as proprietary by the applicant:
• annexes to the dossier which relate to the identity, the production process, composition and
specifications of the NF (see annexes indicated in section 2.1).
• bacterial reverse mutation test (unpublished study report, 2018a), in vitro micronucleus test
(unpublished study report, 2018b, 2019), and 90-day oral toxicity study with the NF
(Unpublished study report, 2018d) including the summary table of the statistically significant
observations in the 90-day study (Appendix B.3 to the dossier). The results of these studies
have been published by Phipps et al. (2018).
Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientific opinion on the safety of lacto-N-tetraose as a novel food. Ref. Ares
(2018)4459745, dated 30/08/2018.
2) On 30/08/2018, a valid application from the European Commission on lacto-N-tetraose as
NF, which was submitted by Glycom A/S, was made available to EFSA by the European
Commission through Commission e-submission portal (NF 2018/0524) and the scientific
evaluation procedure started.
3) On 28/02/2019 and 27/05/2019, EFSA requested the applicant to provide additional
information to accompany the application and the scientific evaluation was suspended.
4) On 10/05/2019 and 21/08/2019, additional information was provided by the applicant and
the scientific evaluation was restarted.
5) During its meeting on 30/10/2019, the NDA Panel, having evaluated the data, adopted a
scientific opinion on the safety of lacto-N-tetraose as a NF pursuant to Regulation (EU)
2015/2283.
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Abbreviations
2’-FL 2’ fucosyllactose
ADME absorption, distribution, metabolism and excretion
ALT alanine aminotransferase
AST aspartate aminotransferase
bw body weight
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CFU colony forming units
DFL difucosyllactose
DRF dose range finding
DSMZ German Collection of Microorganisms and Cell Cultures (Deutsche Sammlung von
Mikroorganismen und Zellkulturen)
EU endotoxin units
Eur.Ph. European pharmacopeia
FAIM Food Additive Intake Model
FL fucosyllactose
FOF follow-on formula
Gal galactose
GlcNAc N-acetylglucosamine
GLP Good Laboratory Practice
GMP Good Manufacturing Practice
GRAS generally recognized as safe
HACCP Hazard Analysis Critical Control Points
HiMO human identical milk oligosaccharides
HiMS human identical milk saccharides
HMO human milk oligosaccharide
HPAEC-PAD high-performance anion exchange chromatography/pulsed amperometric detection
HPLC/CAD high-performance liquid chromatography/charged aerosol detection
HMBC heteronuclear multiple bond correlation
HSQC heteronuclear single quantum coherence
IF infant formula
ISO International Organization for Standardization
KF Karl–Fischer
LC-PUFA long-chain polyunsaturated fatty acids
LNH lacto-N-hexaose
LNT lacto-N-tetraose
LNnT lacto-N-neotetraose
LOQ limit of quantification
LOR limit of reporting
LUC large unstained cells
MCH mean cell haemoglobin
MCHC mean cell haemoglobin concentration
MCV mean cell volume
MS mass spectrometry
GlcNAc N-acetylglucosamine
NF novel food
NOAEL no observed adverse effect level
NOESY nuclear overhauser effect spectroscopy
NMR 1H-nuclear magnetic resonance spectroscopy
OECD Organisation for Economic Co-operation and Development
PAD pulsed amperometric detection
para-LNH-2 para-lacto-N-hexaose-2
PCR polymerase chain reaction
QPS qualified presumption of safety
RBC red blood cells
RDW red cell distribution width
RH relative humidity
RT retention time
SL sialyllactose
UHT ultra-high temperature
UV ultraviolet
WBC white blood cells
zqTOCSY zero quantum total correlation spectroscopy
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Appendix A – Summary results of the 90-day repeated dose toxicity study with the NF
Summary results of parameters with statistically significant differences in the 90-day repeated dose toxicity study
with the NF (unpublished study report, 2018d)
Parameters
Exposure
(day)
Sex Control
Oligofructose control
(4,000 mg/kg bw)
Low dose
(1,000 mg/kg bw)
Mid dose
(2,500 mg/kg bw)
High dose
(4,000 mg/kg bw)
Body weight (g) 4 F 20.3  1.33 21.9  2.89* 20.7  1.96 22.1  1.33* 21.9  2.19*
5 M 23.1  1.58 24.7  2.32* 24.2  2.03 25.0  1.94* 24.3  2.34*
5 F 22.3  1.41 24.2  3.21** 22.6  2.02 24.6  1.29** 23.8  2.39**
6 M 24.8  1.49 27.3  2.53** 26.5  2.42* 27.3  1.84** 26.7  2.57**
6 F 23.8  1.46 26.7  3.53** 24.7  2.20 26.9  1.66** 26.3  2.71**
7 M 26.5  1.95 30.0  2.70** 29.0  2.82** 29.8  2.14** 29.2  2.99**
7 F 25.4  1.75 29.4  3.76** 27.3  2.67 29.4  1.86** 28.8  3.06**
8 M 28.7  2.51 32.1  3.16** 30.8  3.06* 31.7  2.03* 31.1  2.93*
8 F 27.7  2.20 31.5  4.08** 29.2  2.58 31.2  1.82** 30.6  3.07**
9 M 31.5  2.78 33.9  3.59* 33.0  3.77 34.1  2.48* 34.1  3.55*
9 F 30.3  2.45 33.7  4.52** 31.0  2.96 33.4  2.14* 33.6  3.33**
10 M 33.5  2.79 36.4  4.91* 35.1  4.24 37.2  3.13* 36.4  3.64*
10 F 32.2  2.96 35.9  5.53** 32.9  3.33 36.1  2.34** 36.0  3.45**
11 F 34.2  3.85 37.5  5.73* 35.4  3.78 39.0  2.46** 37.7  3.37**
12 F 36.6  4.49 39.6  5.98 37.2  4.34 41.5  2.72** 40.7  3.95**
13 F 40.3  4.93 43.2  6.55 39.1  5.06 45.2  3.73* 43.9  3.93*
15 F 47.6  5.79 50.7  7.54 47.5  5.39 53.2  3.96* 50.8  4.20*
18 F 60.0  6.3 64  8.6 61  6.3 67  4.1* 64  5.4*
22 F 80.0  7.3 83  10.4 81  7.1 88  4.8* 84  7.3*
Food consumption 29-32 M 22.0  2.0 20.0  1.4 21.0  0.7 22.0  0.6 20.0  0.7*
(g/animal/day) 57-60 M 30.0  1.0 28.0  3.1 29.0  0.9 30.0  1.9 27.0  0.8*
60-64 M 29.0  1.1 27.0  2.0 27.0  0.3 29.0  1.5 27.0  0.7*
74-78 M 28.0  1.0 27.0  1.9 27.0  0.2 28.0  0.9 26.0  1.1*
78-81 M 29.0  0.5 27.0  3.0 28.0  0.3 29.0  1.0 27.0  0.2**
Ulna length
(mm)
22 F 25.4  0.48 25.3  0.85 25.0  0.81 25.3  0.56 25.9  0.51*
78 M 40.1  1.15 39.4  1.00 39.8  1.08 39.9  1.12 39.0  0.85**
78 F 37.3  0.88 36.0  0.82** 36.8  1.00 36.4  0.93* 36.3  0.85**
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Parameters
Exposure
(day)
Sex Control
Oligofructose control
(4,000 mg/kg bw)
Low dose
(1,000 mg/kg bw)
Mid dose
(2,500 mg/kg bw)
High dose
(4,000 mg/kg bw)
Sexual maturation
Body weight (g) at vaginal opening F 111  13.5 123  22.2 117  11.7 128  14.4* 121  13.8*
Haematology
Haematocrit (L/L) 90 F 0.417  0.03 0.388  0.02** 0.419  0.02 0.419  0.03 0.388  0.01*
week 4 rec F 0.405  0.02 0.391  0.01 0.401  0.01 0.389  0.02 0.378  0.01*
Haemoglobin (g/dL) week 4 rec F 15.5  0.66 14.9  0.34* 15.3  0.33 14.8  0.51* 14.5  0.32**
Erythrocytes (x1012/L) week 4 rec F 7.57  0.26 7.39  0.26* 7.50  0.14 7.35  0.32 6.86  0.17**
MCH (pg) 90 M 19.3  0.75 19.8  0.56* 19.3  0.59* 19.8  0.85 20.1  0.48*
week 4 rec F 20.5  0.50 20.1  0.56 20.3  0.56 20.1  0.30 21.2  0.45*
MCHC (g/dL) 90 M 35.0  1.69 36.7  0.44* 34.9  1.55 35.3  2.05 37.0  0.79**
F 35.2  1.73 36.5  0.74 35.5  1.73 35.7  1.75 36.9  0.75*
MCV 90 F 56.7  2.24 55.0  1.11* 56.4  1.42 56.7  1.97 54.9  1.77*
week 4 rec F 53.5  1.03 52.9  1.31 53.4  1.54 52.9  1.16 55.1  0.69*
Red cell distribution width (%) 90 F 11.7  0.32 11.4  0.40 11.5  0.53 11.3  0.31* 11.1  0.39**
week 4 rec F 11.2  0.23 11.3  0.13 11.3  0.53 11.2  0.19 11.9  0.78*
Leukocytes (X109/L) 90 M 8.70  1.62 9.39  1.50 10.07  2.13 10.39  1.97 12.67  3.28**
Lymphocytes (X109/L) 90 M 7.13  1.35 8.01  1.33 8.37  1.95 8.51  1.58 10.81  2.85
Eosinophils (X109/L) 90 M 0.08  0.02 0.09  0.04 0.10  0.04* 0.07  0.03 0.12  0.05*
LUC (X109/L) 90 M 0.05  0.02 0.06  0.02 0.06  0.03 0.06  0.03 0.08  0.04*
Platelet count (X109/L) 90 M 886  75.7 959  77.4* 961  57.5 918  57.0 969  97.7*
Clinical chemistry parameters
ALT (U/L) 90 M 31  4.5 34  2.4 30  3.6 36  6.4* 36  5.6
AST (U/L) 90 F 90  9.3 84  12.2 79  8.3 72  7.1* 101  64.6*
Urea (mmol/L) 90 M 6.01  0.98 4.38  0.35** 6.05  0.74 7.06  0.68** 5.21  0.54*
90 F 7.13  0.98 5.74  0.69** 7.03  0.80 7.14  0.94 6.22  0.38*
Creatinine (lmol/L) 90 F 33  4.4 28  2.4* 30  2.5 29  4.0** 28  3.2**
week 4 rec F 37  4.7 31  2.6** 29  2.9 35  2.7* 31  3.0*
Cholesterol (mmol/L) 90 M 1.31  0.22 1.44  0.23 1.28  0.25 1.24  0.22 1.60  0.32*
Potassium (mmol/L) 90 M 4.7  0.30 4.5  0.27 4.7  0.13 4.7  0.31 4.4  0.27*
Chloride (mmol/L) 90 F 98  1.4 99  2.1 98  0.8 98  0.9 100  2.3**
week 4 rec M 99  1.2 100  1.0 100  0.8 100  1.2 101  0.5*
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Parameters
Exposure
(day)
Sex Control
Oligofructose control
(4,000 mg/kg bw)
Low dose
(1,000 mg/kg bw)
Mid dose
(2,500 mg/kg bw)
High dose
(4,000 mg/kg bw)
Calcium (mmol/L) 90 M 2.53  0.03 2.59  0.07* 2.60  0.06 2.55  0.1 2.64  0.06**
Inorganic phosphorus (mmol/L) 90 M 2.06  0.24 2.31  0.24 2.15  0.27 2.17  0.30 2.42  0.19
A/G (Ratio) week 4 rec M 1.01  0.09 1.02  0.09 1.06  0.09 1.03  0.09 1.14  0.10*
Urinalysis
Volume (mL) 90 F 4.8  1.78 5.8  2.45 5.5  1.06 6.4  2.58 7.5  2.92*
pH 90 F 6.7  0.24 7.1  0.72 7.2  0.30 7.2  0.41 7.6  0.61**
Specific gravity (g/L) 90 M 1029  5.3 1024  3.9 1028  4.8 1024  3.9* 1024  5.9*
90 F 1037  6.9 1028  10.6 1030  2.9 1029  8.3* 1024  4.7**
Total proteins (mg) 90 M 6.77  3.22 5.89  2.16 6.11  1.54* 7.61  3.21* 6.68  2.35**
Organ weight (adjusted mean values) –
Kidneys (g) week 4 rec F 1.97 2.05 2.08 2.12 2.17*3
Liver (g) week 4 rec F 10.57 10.92 11.19 11.04 12.48*
Ovaries (g) week 4 rec F 0.088 0.104* 0.089 0.098 0.108**
Pituitary (g) week 4 rec M 0.016 0.015 0.015 0.014* 0.013*
Spleen (g) week 4 rec F 0.566 0.605 0.536 0.538 0.725*
Testes (g) 90 M 3.380 3.548* 3.465 3.723* 3.580*
MCH: mean cell haemoglobin; MCHC: mean cell haemoglobin concentration; MCV: mean cell volume; RDW: red cell distribution width; LUC: large unstained cells; ALT: alanine aminotransferase;
AST: aspartate aminotransferase; A/G: albumin/globulin ratio.
*: Significantly different from control (p < 0.05) (Vehicle control vs LNT-treated groups or reference control);
**: Significantly different from control (p < 0.01) (control vs LNT-treated groups or reference control).
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